LENZ THERAPEUTICS INC
LENZ · NASDAQ
Updated at 2026-10-15 05:47:30
- Today's High
- $3.61
- Today’s Low
- $3.34
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $3.39
- Previous Close
- $3.43
- Volume
- 1.03M
- Market Cap
- $107.77M
- P/E Ratio
- --
- EPS
- $-4.08
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Pharmaceuticals
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 201 LOMAS SANTA FE DRIVE, SOLANA BEACH, CA, UNITED STATES, 92075
- Country
- US
- Listing Date
- 2021-06-25
- Fiscal Year End
- December
- Shares Outstanding
- 31.35M
- CIK
- 0001815776
- Website
- lenz-tx.com
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical unmet needs in the central nervous system (CNS). The company employs advanced drug formulation and delivery technologies to support a robust pipeline of proprietary assets, aiming to enhance patient outcomes and address significant healthcare challenges. With a strong focus on strategic partnerships and a commitment to rigorous clinical research, LENZ is strategically positioned for significant growth and aspires to become a key player in the biopharmaceutical landscape, leveraging emerging opportunities in the dynamic healthcare market.
Financial Metrics
Revenue
2026-06-30
$5.48M
2026-03-31
$1.9M
2025-12-31
$1.58M
2025-09-30
$12.5M
Operating Expenses
2026-06-30
$39.37M
2026-03-31
$44.84M
2025-12-31
$39.52M
2025-09-30
$31.26M
Net Income
2026-06-30
-$31.91M
2026-03-31
-$41.48M
2025-12-31
-$35.89M
2025-09-30
-$16.7M
Net Profit Margin
2026-06-30
-581.8%
2026-03-31
-2.18K%
2025-12-31
-2.26K%
2025-09-30
-133.6%
Earnings Per Share
2026-06-30
$-1.02
2026-03-31
$-1.32
2025-12-31
$-1.16
2025-09-30
$-0.59
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$31.8M
2026-03-31
-$41.37M
2025-12-31
-$35.78M
2025-09-30
-$16.57M
Effective Tax Rate
2026-06-30
0%
2026-03-31
--
2025-12-31
0%
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $5.48M | $1.9M | $1.58M | $12.5M |
| Operating Expenses | $39.37M | $44.84M | $39.52M | $31.26M |
| Net Income | -$31.91M | -$41.48M | -$35.89M | -$16.7M |
| Net Profit Margin | -581.8% | -2.18K% | -2.26K% | -133.6% |
| Earnings Per Share | $-1.02 | $-1.32 | $-1.16 | $-0.59 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$31.8M | -$41.37M | -$35.78M | -$16.57M |
| Effective Tax Rate | 0% | -- | 0% | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.